- Details
- Alicia Morgans, MD, MPH, welcomes Bradley McGregor, MD, to discuss the use of an antibody-drug conjugate for frontline kidney cancer treatment. Dr. McGregor gives insight into a unique target, TIM-1, strategically expressed on renal cell carcinoma but not in healthy kidney tissue. He describes a phase 1 study that assessed the dosage for the antibody-drug conjugate. The TIM-1 target requires furth...
|
- Details
- The development of novel combination therapies in kidney cancer is on the rise due to the approval of combination immunotherapies. Joining Alicia Morgans is Chung-Han (Joe) Lee, who highlights his recent advancements in TKI-IO combination therapies. Dr. Lee also concentrates on the responses of biomarkers with aims to aid in personalized treatment for kidney cancer patients, especially those for n...
|
- Details
- Following presentations at the ASCO 2020 Virtual Annual Meeting, Toni Choueiri, MD, discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma. The phase II OMNIVORE study enrolled patients with advanced RCC and no prior checkpoint inhibit...
|
- Details
- Clear cell renal carcinoma has a modest tumor mutational burden and increased infiltration of CD8+ T cells which is associated with worse prognosis in this disease. Biomarkers for response to immune checkpoint inhibitors are needed to predict which patients will respond. David Braun joins Alicia Morgans and overviews his ASCO 2020 presentation on the genomic and immune determinants of response to...
|
- Details
- It is unknown what the optimal duration of nivolumab maintenance is to sustain disease control and what the response rate to single-agent nivolumab is for treatment naïve patients with metastatic renal cell carcinoma (mRCC). OMNIVORE a response-based phase II study seeks to help answer some of these questions. This study enrolled patients with treatment-naïve or previously treated advanced RCC (aR...
|
- Details
- Brian Rini joins Charles Ryan to discuss frontline therapy in kidney cancer, specifically focusing on the recent updates on the combination of axitinib and pembrolizumab in the Keynote-426 data. KEYNOTE-426 study, which is at the two-year mark of followup, is a randomized, open-label, phase 3 study that demonstrated that pembrolizumab (pembro) + axitinib (axi) significantly improved overall surviv...
|
- Details
- In this episode of Kidney Cancer Today, Bradley McGregor joins Monty Pal and Jaime Landman to speak about the major practice-changing studies that have come out over the past year in the frontline setting and the evolution of therapy in the renal cell carcinoma space. Biographies: Bradley McGregor, MD, Clinical Director, Senior Physician, Instructor in Medicine, Lank Center for Genitourinary Oncol...
|
- Details
- Rana McKay and Monty Pal share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation. Biographies: Rana R. McKay, MD, Medical Oncologist, Assistant Professor of Medicine, UC San Diego Health Sumanta Kumar Pal, MD Associate Clinical Profe...
|
- Details
- Darren Feldman, MD, and Alicia Morgans, MD, MPH, discuss the nuances of treating non-clear cell kidney cancer, a disease that has historically been underrepresented in phase 3 clinical trials of kidney cancer and is also histologically heterogeneous. This heterogeneity makes variations of the disease rare, and thus single-agent VEGF Tyrosine Kinase Inhibitors (TKIs) aren't always effective. Dr. Fe...
|
- Details
- Che-Kai Tsao, MD, and Alicia Morgans, MD, MPH, sit down to discuss emerging therapeutic options for kidney cancer, specifically focused on patient groups that haven’t historically qualified for targeted treatments. Dr. Tsao highlights a new wealth of treatment options, honing in on checkpoint inhibitors for metastatic kidney cancer — specifically clear cell — and reviewing ongoing and accruing tri...
|
